Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1803-1812

  Copeland, Ben T ^a   Bowman, Matthew J ^a   Boucheix, Claude ^b,c   Ashman, Leonie K ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

cancer; CD9; metastasis; prostate; tetraspanin

Indexed keywords

TETRASPANIN;

ABLATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER STAGING; CARCINOGENESIS; CD9 GENE; CELL ADHESION; CELL MOTILITY; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE INACTIVATION; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

CANCER; CD9; METASTASIS; PROSTATE; TETRASPANIN;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD9; APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; GENE KNOCKOUT TECHNIQUES; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS;

EID: 84881551872     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28204     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. Cancer J Clin 2012; 62: 10-29.
2. Valastyan S, Weinberg Robert A,. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-92.
3. Hemler ME,. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005; 6: 801-11.
4. Zoller M,. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009; 9: 40-55.
5. Boucheix C, Rubinstein E,. Tetraspanins. Cell Mol Life Sci 2001; 58: 1189-205.
6. Sincock PM, Mayrhofer G, Ashman LK,. Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63, and alpha5 beta1 integrin. J Histochem Cytochem 1997; 45: 515-26.
7. Powner D, Kopp P, Monkley S, et al. Tetraspanin CD9 in cell migration. Biochem Soc Trans 2011; 39: 563-7.
8. Wang J-C, Begin LR, Berube NG, et al. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res 2007; 13: 2354-61.
9. Chuan Y, Pang S, Bergh A, et al. Androgens induce CD-9 in human prostate tissue. Int J Androl 2005; 28: 291-6.
10. Miyake M, Nakano K, Itoi S, et al. Motility related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 1996; 56: 1244-9.
11. Miyake M, Nakano K, Ieki Y, et al. Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res 1995; 55: 4127-31.
12. Higashiyama M, Doi O, Kodama K, et al. Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 1997; 74: 205-11.
13. Higashiyama M, Taki T, Ieki Y, et al. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 1995; 55: 6040-4.
14. Cajot J, Sordat I, Silvestre T, et al. Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res 1997; 57: 2593-7.
15. Hashida H, Takabayashi A, Tokuhara T, et al. Integrin a3 expression as a prognostic factor in colon cancer:association with MRP-1/CD9 and KAI1/CD82. Int J Cancer 2002; 97: 518-25.
16. Mori M, Mimori K, Shiraishi T, et al. Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 1998; 4: 1507-10.
17. Kusukawa J, Ryu F, Kameyama T, et al. Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis. J Oral Pathol Med 2001; 30: 73-9.
18. Mhawech P, Dulguerov P, Tschanz E, et al. Motility-related protein-1 (MRP-1/CD9) expression can predict disease-free survival in patients with squamous cell carcinoma of the head and neck. Br J Cancer 2004; 90: 471-5.
19. Erovic BM, Pammer J, Hollemann D, et al. Motility-related protein-1/CD9 expression in head and neck squamous cell carcinoma. Head Neck 2003; 25: 848-57.
20. Mhawech P, Herrmann F, Coassin M, et al. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer 2003; 98: 1649-57.
21. De, Bruyne E, Bos TJ, Asosingh K, et al. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 2008; 14: 2918-26.
22. Zou Q, Xiong L, Yang Z, et al. Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder. World J Surg Oncol 2012; 10: 92.
23. Sauer G, Windisch J, Kurzeder C, et al. Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 2003; 9: 6426-31.
24. Soyuer S, Soyuer I, Unal D, et al. Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy. Pathol Res Pract 2010; 206: 607-10.
25. Hori H, Yano S, Koufuji K, et al. CD9 expression in gastric cancer and its significance. J Surg Res 2004; 117: 208-15.
26. Kubista B, Erovic BM, Klinger H, et al. CD9 expression is not a prognostic factor in human osteosarcoma. Cancer Lett 2004; 209: 105-10.
27. Zhang J, Dong J, Gu H, et al. CD9 Is critical for cutaneous wound healing through JNK signaling. J Invest Dermatol 2012; 132: 226-36.
28. Zvieriev V, Wang J-C, Chevrette M,. Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells. Biochem Biophys Res Commun 2005; 337: 498-504.
29. Le Naour F, Rubinstein E, Jasmin C, et al. Severely reduced female fertility in CD9-deficient mice. Science 2000; 287: 319-21.
30. Rubinstein E, Ziyyat A, Prenant M, et al. Reduced fertility of female mice lacking CD81. Dev Biol 2006; 290: 351-8.
31. Mangin PH, Kleitz L, Boucheix C, et al. CD9 negatively regulates integrin αIIbβ3 activation and could thus prevent excessive platelet recruitment at sites of vascular injury. J Thromb Haemost 2009; 7: 900-2.
32. Suzuki M, Tachibana I, Takeda Y, et al. Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation. J Immunol 2009; 182: 6485-93.
33. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439-43.
34. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096-102.
35. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003; 55: 219-37.
36. Copeland BT, Bowman MJ, Ashman LK,. Genetic ablation of the tetraspanin CD151 reduces spontaneous metastatic spread of prostate cancer in the TRAMP model. Mol Cancer Res 2013; 11: 95-105.
37. Chiaverotti T, Couto SS, Donjacour A, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008; 172: 236-47.
38. Huss WJ, Grayy DR, Tavakoli K, et al. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007; 9: 938-50.
39. Gingrich J, Barrios R, Foster B, et al. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Disord 1999; 2: 70-7.
40. Miyado K, Yamada G, Yamada S, et al. Requirement of CD9 on the egg plasma membrane for fertilization. Science 2000; 287: 321-4.
41. Huang C-l, Liu D, Masuya D, et al. MRP-1/CD9 gene transduction downregulates Wnt signal pathways. Oncogene 2004; 23: 7475-83.
42. Nakazawa Y, Sato S, Naito M, et al. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood 2008; 112: 1730-9.
43. Kamisasanuki T, Tokushige S, Terasaki H, et al. Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy. Biochem Biophys Res Commun 2011; 413: 128-35.
44. Longo N, Yáñez-Mõ Ma, Mittelbrunn Ma, et al. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 2001; 98: 3717-26.
45. Ikeyama S, Koyama M, Yamaoko M, et al. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 1993; 177: 1231-7.
46. Miyake M, Inufusa H, Adachi M, et al. Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery. Oncogene 2000; 19: 5221-6.
47. Takeda T, Hattori N, Tokuhara T, et al. Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. Cancer Res 2007; 67: 1744-9.
48. Zheng R, Yano S, Zhang H, et al. CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncol Res 2005; 15: 365-72.
49. Nakamoto T, Murayama Y, Oritani K, et al. A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol 2009; 44: 889-96.
50. Rubinstein E,. The complexity of tetraspanins. Biochem Soc Trans 2011; 39: 501-5.
51. Sadej R, Romanska H, Kavanagh D, et al. Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res 2010; 70: 6059-70.